Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors

Haemophilia

Volumn 18, Issue 6, 2012, Pages

  Salaj, P ^a   Ovesna, P ^b   Penka, M ^c   Hedner, U ^d  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANALGESIC AGENT; BLOOD CLOTTING FACTOR 7; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHRALGIA; BLEEDING; CLINICAL PRACTICE; CZECH REPUBLIC; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; HEALTH SURVEY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIC ARTHROPATHY; HUMAN; LETTER; NUMERICAL RATING PAIN SCALE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; RISK REDUCTION; SCORING SYSTEM;

ACUTE PAIN; ANALGESICS; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIIA; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84868207600     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02920.x     Document Type: Letter

References (10)

1. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
2. van Genderen FR, Fischer K, Heijnen L et al. Pain and functional limitations in patients with severe haemophilia. Haemophilia 2006; 12: 147-53.
3. Knight C, Dano AM, Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther 2009; 26: 68-88.
4. Salek SZ, Benson GM, Elezovic I et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia 2011; 17: 95-102.
5. The Haemophilia Society. Pain Management. Available at: http://www.youngbloods.org.uk/Resources/Haemophilia%20Youth/Pain%20management.pdf. Accessed June 18, 2012.
6. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.
7. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
8. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
9. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-57.
10. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441-51.